Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

太美医疗科技

Zhejiang Taimei Medical Technology Co., Ltd.

浙江太美醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2576)

VOLUNTARY ANNOUNCEMENT

CHANGE OF CHIEF FINANCIAL OFFICER

The board (the "**Board**") of directors (each a "**Director**") of Zhejiang Taimei Medical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") recently received a resignation letter from Mr. JIANG Chengwen (姜程文) ("**Mr. Jiang**") to resign as the chief financial officer of the Company with effect from July 25, 2025, due to his other personal commitments. Upon his resignation as the chief financial officer of the Company having taken effect, Mr. Jiang will no longer hold any position within the Group. Mr. Jiang has confirmed that he has no disagreement with the Board, and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its heartfelt gratitude to Mr. Jiang for his valuable contribution to the Group during his tenure.

On July 25, 2025, the Board resolved to appoint Mr. WANG Wei (王為) ("**Mr. Wang**") as the chief financial officer of the Company with effect from the same date. Details of Mr. Wang are set out as follows:

Mr. WANG Wei (王為), aged 36, will be primarily responsible for strategic financial planning and overseeing the financial management of the Group. Mr. Wang has over ten years of experience in transaction execution in both China onshore and offshore capital markets, with a presence in Hong Kong and Shanghai. Prior to joining the Group, from March 2015 to February 2018, he served at BNP Paribas (China) Limited (法國巴黎銀行(中國)有限公司), where he last served as a debt capital markets associate. From April 2018 to June 2021, he served at CLSA LIMITED (中信里昂證券有限公司), where he last served as a senior associate at the corporate finance and capital markets division. From July 2021 to February 2023, Mr. Wang served as a vice president at the investment banking and capital markets division at Credit Suisse Securities (China) Limited (瑞信證券(中國)有限公司), where he was primarily responsible for executing equity and debt financing transactions for Chinese enterprises in the offshore capital markets. From March 2023 to June 2024, he served as an executive director at Walden Partners (Hong Kong) Limited, a financial institution principally engaged in advising on cross-border mergers and acquisitions ("**M&A**"), where he was primarily responsible for facilitating and executing cross-border M&A transactions

for Chinese enterprises. From July 2024 to June 2025, he served as the board secretary and the head of investment and M&A at Shanghai Ushopal Brand Holding Group Co., Ltd (上海深屹實業集團股份有限公司), a luxury beauty brand group, where he was primarily responsible for leading the company's strategic financing and cross-border M&A transactions.

Mr. Wang obtained his bachelor's degree in computer science and technology from Fudan University (復旦大學) in Shanghai in June 2011. He obtained his master's degree in economics from the University of Edinburgh in the United Kingdom in November 2012 and further obtained his MPhil degree in economic research from the University of Cambridge in the United Kingdom in February 2015.

The Board would like to express its warmest welcome to Mr. Wang for joining the Group.

By Order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Mr. ZHAO Lu
Chairman of the Board

Hong Kong, July 25, 2025

As at the date of this announcement, the Board comprises Mr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Mr. HUANG Yufei and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Dr. LI Zhiguo and Mr. FUNG Che Wai Anthony as independent non-executive Directors.